EP0473707A1 - Composition de clarithromycine injectable - Google Patents

Composition de clarithromycine injectable

Info

Publication number
EP0473707A1
EP0473707A1 EP90909022A EP90909022A EP0473707A1 EP 0473707 A1 EP0473707 A1 EP 0473707A1 EP 90909022 A EP90909022 A EP 90909022A EP 90909022 A EP90909022 A EP 90909022A EP 0473707 A1 EP0473707 A1 EP 0473707A1
Authority
EP
European Patent Office
Prior art keywords
composition
clarithromycin
acid
oil
stabilizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90909022A
Other languages
German (de)
English (en)
Other versions
EP0473707A4 (en
Inventor
Ho-Wah Hui
Chung-Chiang Hsu
John B. Cannon
Michael W. Lovell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP0473707A1 publication Critical patent/EP0473707A1/fr
Publication of EP0473707A4 publication Critical patent/EP0473707A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10C—WORKING-UP PITCH, ASPHALT, BITUMEN, TAR; PYROLIGNEOUS ACID
    • C10C3/00—Working-up pitch, asphalt, bitumen
    • C10C3/002—Working-up pitch, asphalt, bitumen by thermal means
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10C—WORKING-UP PITCH, ASPHALT, BITUMEN, TAR; PYROLIGNEOUS ACID
    • C10C3/00—Working-up pitch, asphalt, bitumen
    • C10C3/06—Working-up pitch, asphalt, bitumen by distillation
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • D01F9/08—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
    • D01F9/12—Carbon filaments; Apparatus specially adapted for the manufacture thereof
    • D01F9/14—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments
    • D01F9/145—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments from pitch or distillation residues
    • D01F9/155—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments from pitch or distillation residues from petroleum pitch

Abstract

On a mis au point un médicament injectable administré par voie intraveineuse ou intramusculaire, comprenant une concentration thérapeutiquement efficace de clarithromycine, ainsi qu'une huile de triglycéride et un agent stabilisant.
EP19900909022 1989-05-26 1990-05-25 Injectable clarithromycin composition Withdrawn EP0473707A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35828389A 1989-05-26 1989-05-26
US358283 1989-05-26

Publications (2)

Publication Number Publication Date
EP0473707A1 true EP0473707A1 (fr) 1992-03-11
EP0473707A4 EP0473707A4 (en) 1992-12-09

Family

ID=23409043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900909022 Withdrawn EP0473707A4 (en) 1989-05-26 1990-05-25 Injectable clarithromycin composition

Country Status (9)

Country Link
EP (1) EP0473707A4 (fr)
JP (1) JP2963537B2 (fr)
KR (1) KR920700655A (fr)
AU (1) AU630469B2 (fr)
CA (1) CA2056445A1 (fr)
GR (1) GR1002177B (fr)
IL (1) IL94516A (fr)
NZ (1) NZ233827A (fr)
WO (1) WO1990014094A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
DE4447972B4 (de) * 1993-05-27 2007-12-27 Novartis Ag Galenische Formulierungen
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4410637C1 (de) * 1994-03-26 1995-09-21 Boehringer Ingelheim Vetmed Injizierbare Lösungen von Dirithromycin
US5795871A (en) * 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
WO2003049716A1 (fr) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Formulation topique stable de clarithromycine
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2007102241A1 (fr) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. Composition pharmaceutique externe
CA2645070C (fr) * 2006-03-08 2014-02-04 Nihon Nohyaku Co., Ltd. Composition pharmaceutique pour usage externe
ES2591030T3 (es) 2007-09-05 2016-11-24 Pola Pharma Inc. Composición farmacéutica antifúngica
JP5345937B2 (ja) 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
WO2009031642A1 (fr) 2007-09-05 2009-03-12 Pola Pharma Inc. Composition pharmaceutique
EP2416757A2 (fr) 2009-04-09 2012-02-15 Pola Pharma Inc. Composition pharmaceutique antimycotique
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
KR101754697B1 (ko) 2009-08-25 2017-07-06 가부시키가이샤 폴라 파마 항진균성 약제학적 조성물
CN105658203B (zh) 2013-11-08 2021-03-16 株式会社活效制药 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂
CN110234322A (zh) * 2017-04-03 2019-09-13 消化系统疾病中心 用于治疗链球菌感染以治疗牛皮癣的抗生素化合物的施用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302370A1 (fr) * 1987-08-07 1989-02-08 Abbott Laboratories Formulations d'erythromycine pour l'administration orale
EP0361928A2 (fr) * 1988-09-29 1990-04-04 Shiseido Company Limited Composition émulsifiée

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61291520A (ja) * 1985-06-19 1986-12-22 Daigo Eiyou Kagaku Kk エリスロマイシン脂肪乳剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302370A1 (fr) * 1987-08-07 1989-02-08 Abbott Laboratories Formulations d'erythromycine pour l'administration orale
EP0361928A2 (fr) * 1988-09-29 1990-04-04 Shiseido Company Limited Composition émulsifiée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9014094A1 *

Also Published As

Publication number Publication date
WO1990014094A1 (fr) 1990-11-29
JPH04505762A (ja) 1992-10-08
IL94516A (en) 1994-12-29
GR1002177B (en) 1996-03-07
EP0473707A4 (en) 1992-12-09
AU5811090A (en) 1990-12-18
CA2056445A1 (fr) 1990-11-27
AU630469B2 (en) 1992-10-29
IL94516A0 (en) 1991-03-10
NZ233827A (en) 1991-06-25
JP2963537B2 (ja) 1999-10-18
GR900100402A (el) 1991-10-10
KR920700655A (ko) 1992-08-10

Similar Documents

Publication Publication Date Title
AU630469B2 (en) Injectable clarithromycin composition
US5085864A (en) Injectable formulation for lipophilic drugs
US5474979A (en) Nonirritating emulsions for sensitive tissue
EP0215313B1 (fr) Emulsions pour l'administration parentérale et/ou orale de médicaments peu solubles dans l'eau, ionisables et hydrophobes
NO844144L (no) Legemiddeltilberedning
JP2002527465A (ja) ペンテチン酸塩を含有するプロポフォール組成物
US20080132582A1 (en) Propofol formulation containing reduced oil and surfactants
JPS6144809A (ja) ４−ビフエニリル酢酸系化合物含有脂肪乳剤
FR2706772A1 (en) Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US4849451A (en) Fat emulsion containing prostaglandin
JP2007501253A (ja) マクロライド含有水中油エマルジョン
EP0426029A1 (fr) Compositions injectables contenant des médicaments lipophiles
EP0257454A1 (fr) Emulsion grasse du type huile-dans-eau de 1-[2-(2,4-dichlorophényl)-3-méthyl-1-pentényl]-1H-imidazole
JP2939082B2 (ja) 安定なビタミンａパルミテート及びビタミンｅ類可溶化点眼剤
EP0418004B1 (fr) Agent préventif et thérapeutique pour l'hépatite
JP3132085B2 (ja) 脂肪乳剤
EP1377315B1 (fr) Compositions pharmaceutiques de rapamycines
JPS63319046A (ja) 被覆脂肪乳剤
Levy et al. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis
AU737983B2 (en) An oil composition of dihydropolyprenols
JPH06227990A (ja) 安定な局所的処方剤
JPH1160491A (ja) アムホテリシンｂ含有製剤
EP1165046A1 (fr) Compositions de propofol contenant des additifs de preservation
JP2002020268A (ja) 脂溶性物質含有内服液剤
KR20000073825A (ko) 클라리스로마이신-함유 건조리포좀 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19921022

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950331